Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BFRG |
---|---|---|
09:32 ET | 100 | 2.5 |
09:33 ET | 870 | 2.4653 |
09:35 ET | 1000 | 2.495 |
09:37 ET | 500 | 2.5104 |
09:39 ET | 200 | 2.53 |
09:55 ET | 3496 | 2.5 |
10:00 ET | 3313 | 2.49 |
10:18 ET | 500 | 2.5366 |
10:22 ET | 2000 | 2.4919 |
10:33 ET | 124 | 2.533 |
10:36 ET | 150 | 2.5337 |
10:44 ET | 1241 | 2.4901 |
10:51 ET | 200 | 2.53 |
11:00 ET | 1198 | 2.4901 |
11:02 ET | 2200 | 2.51 |
11:03 ET | 100 | 2.4901 |
11:18 ET | 2397 | 2.47 |
11:20 ET | 3264 | 2.46 |
11:27 ET | 100 | 2.5399 |
11:39 ET | 851 | 2.5 |
12:08 ET | 3000 | 2.4501 |
12:12 ET | 550 | 2.46 |
12:53 ET | 100 | 2.5195 |
12:55 ET | 100 | 2.5299 |
12:57 ET | 100 | 2.5211 |
01:27 ET | 1000 | 2.4538 |
01:36 ET | 100 | 2.46 |
01:38 ET | 2000 | 2.49 |
01:47 ET | 100 | 2.52 |
02:25 ET | 100 | 2.5 |
02:30 ET | 1000 | 2.4811 |
02:34 ET | 612 | 2.4621 |
02:41 ET | 2421 | 2.4646 |
02:48 ET | 2000 | 2.46 |
02:57 ET | 12228 | 2.49 |
02:59 ET | 1140 | 2.426 |
03:03 ET | 100 | 2.48 |
03:10 ET | 100 | 2.45 |
03:12 ET | 300 | 2.4 |
03:17 ET | 100 | 2.4517 |
03:46 ET | 400 | 2.44 |
03:51 ET | 467 | 2.43 |
03:53 ET | 420 | 2.41 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Bullfrog AI Holdings, Inc. | 14.7M | -2.9x | --- |
Microbot Medical Inc | 14.6M | -1.0x | --- |
NLS Pharmaceutics AG | 14.9M | -0.5x | --- |
Hepion Pharmaceuticals Inc | 14.4M | -0.3x | --- |
Bioxytran Inc | 15.1M | -3.4x | --- |
Mustang Bio Inc | 14.2M | -0.2x | --- |
Bullfrog AI Holdings, Inc. is a digital biopharmaceutical company. The Company is focused on advanced artificial intelligence/machine learning (AI/ML)-driven analysis of complex data sets in medicine and healthcare. The Company’s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&D and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. The Company’s therapeutic pipeline includes siRNA and Mebendazole. Its siRNA targets Beta2-spectrin in the treatment of human diseases such as hepatocellular carcinoma (HCC), obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $14.7M |
---|---|
Revenue (TTM) | $75.0K |
Shares Outstanding | 6.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.84 |
Book Value | $-0.50 |
P/E Ratio | -2.9x |
Price/Sales (TTM) | 195.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -6,153.07% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.